

## Aortic–Brachial Arterial Stiffness Gradient and Cardiovascular Risk in the Community The Framingham Heart Study

Teemu J. Niiranen, Bindu Kalesan, Martin G. Larson, Naomi M. Hamburg, Emelia J. Benjamin, Gary F. Mitchell, Ramachandran S. Vasani

**Abstract**—A recent study reported that the aortic–brachial arterial stiffness gradient, defined as carotid–radial/carotid–femoral pulse wave velocity (PWV ratio), predicts all-cause mortality better than carotid–femoral pulse wave velocity (CFPWV) alone in dialysis patients. However, the prognostic significance of PWV ratio for cardiovascular disease (CVD) in the community remains unclear. Accordingly, we assessed the correlates and prognostic value of the PWV ratio in 2114 Framingham Heart Study participants (60±10 years; 56% women) free of overt CVD. Mean PWV ratio decreased from 1.36±0.19 in participants aged <40 years to 0.73±0.21 in those aged ≥80 years. In multivariable linear regression, older age, male sex, higher body mass index, diabetes mellitus, lower high-density lipoprotein cholesterol, higher mean arterial pressure, and higher heart rate were associated with lower PWV ratio ( $P<0.001$  for all). During a median follow-up of 12.6 years, 248 first CVD events occurred. In Cox regression models adjusted for standard CVD risk factors, 1-SD changes in CFPWV (hazard ratio, 1.33; 95% confidence interval, 1.10–1.61) and PWV ratio (hazard ratio, 1.32; 95% confidence interval, 1.09–1.59) were associated with similar CVD risks. Models that included conventional CVD risk factors plus CFPWV or PWV ratio gave the same C statistics ( $C=0.783$ ). Although PWV ratio has been reported to provide incremental predictive value over CFPWV in dialysis patients, we could not replicate these findings in our community-based sample. Our findings suggest that the prognostic significance of PWV ratio may vary based on baseline CVD risk, and CFPWV should remain the criterion standard for assessing vascular stiffness in the community. (*Hypertension*. 2017;69:1022–1028. DOI: 10.1161/HYPERTENSIONAHA.116.08917.) • [Online Data Supplement](#)

**Key Words:** blood pressure ■ cardiovascular diseases ■ epidemiology ■ hypertension ■ risk factors  
■ vascular stiffness

Under physiological conditions, the arterial vasculature is characterized by a progressive increase in stiffness from the aorta and large elastic arteries toward the peripheral muscular conduit arteries, often labeled as the arterial stiffness gradient.<sup>1,2</sup> However, this gradient is not by any means invariable as stiffness of the aorta tends to increase with age, whereas the relationship between peripheral muscular arteries and advancing age is not as pronounced.<sup>1,3–5</sup> In fact, upper-limb muscular artery compliance may even decrease with age in women and in individuals with diabetes mellitus.<sup>6,7</sup> Age-related changes in vasculature thereby result in a reduction, or even a reversal of the physiological arterial stiffness gradient in most individuals.<sup>1,5</sup>

Increased aortic stiffness, most commonly measured as the carotid–femoral pulse wave velocity (CFPWV), is a strong

predictor of cardiovascular disease (CVD) both in patient and population-based cohorts.<sup>8–11</sup> In contrast, it is unclear whether muscular conduit artery stiffness, often measured in the arm as the carotid–radial pulse wave velocity (CRPWV), is associated with cardiovascular morbidity.<sup>2,12–14</sup> Although CRPWV has been largely overshadowed in research and clinical practice by CFPWV because of its limited prognostic value, recent research suggests that CRPWV may, after all, also have an important role in CVD risk prediction. Specifically, a recent study by Fortier et al<sup>14</sup> reported that an increased aortic–brachial arterial stiffness gradient (defined as the ratio of CFPWV and CRPWV) was a better predictor of all-cause mortality than CFPWV per se.

Fortier et al<sup>14</sup> and Covic and Siriopol<sup>15</sup> of an accompanying editorial speculated that the finding of a clinically significant

Received December 23, 2016; first decision January 13, 2017; revision accepted March 8, 2017.

From the National Heart, Blood and Lung Institute's and Boston University's Framingham Heart Study, Framingham, MA (T.J.N., M.G.L., E.J.B., R.S.V.); Center for Clinical Translational Epidemiology and Comparative Effectiveness Research (B.K., R.S.V.), Section of Preventive Medicine, Department of Medicine (B.K., E.J.B., R.S.V.), Department of Biostatistics (M.G.L.), Evans Department of Medicine and Whitaker Cardiovascular Institute (N.M.H., E.J.B., R.S.V.), Section of Cardiology, Department of Medicine (N.M.H., E.J.B., R.S.V.), Section of Vascular Biology, Department of Medicine (N.M.H.), and Department of Epidemiology (E.J.B., R.S.V.), Boston University School of Public Health, MA; and Cardiovascular Engineering, Inc., Norwood, MA (G.F.M.).

The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.116.08917/-DC1>.

Correspondence to Teemu J. Niiranen, Framingham Heart Study, 73 Mt. Wayte Avenue, Suite 2, Framingham, MA 01702. E-mail [teemu.niiranen@thl.fi](mailto:teemu.niiranen@thl.fi)  
© 2017 American Heart Association, Inc.

*Hypertension* is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.116.08917

interaction between elastic and muscular arteries could open a new area for future research, and both agreed that the role of the arterial stiffness gradient as a cardiovascular risk factor needs validation in the community. Therefore, we evaluated whether the aortic–brachial arterial stiffness gradient incrementally predicts CVD beyond conventional CFPWV in community-dwelling participants in the Framingham Heart Study Offspring cohort.

## Methods

### Participants

The Framingham Heart Study Offspring cohort consists of the children of individuals in the Original Framingham cohort, along with their spouses.<sup>16</sup> The baseline characteristics and more detailed study protocol for the Framingham Offspring cohort have been previously published.<sup>16</sup> We included participants who attended the seventh examination cycle of the Framingham Offspring cohort (n=3539; 1998–2001) in the present investigation. Because of a delayed start, tonometry measurements were implemented in 2660 of 3539 participants during the study cycle beginning in February 1999. We excluded participants who had incomplete tonometry data (n=372) or prevalent CVD (n=174) from the present analysis resulting in a final study sample of 2114 participants. The study was conducted according to the Declaration of Helsinki. All study protocols were reviewed and approved by Boston University Medical Center's Institutional Review Board, and participants provided written informed consent.

### Clinical Evaluation and Definitions

The participants provided medical history and underwent physical examination and assessment of CVD risk factors.<sup>16</sup> The participants were using their normal CVD medications at the time of PWV measurements. We assessed participants for self-reported cigarette use in the year preceding the examination and diabetes mellitus (fasting glucose level of  $\geq 126$  mg/dL or the use of hypoglycemic medications). In addition, we measured blood pressure (mean of 2 auscultatory values measured by a physician with a mercury column sphygmomanometer on seated participants using a standardized protocol), body mass index (BMI), serum total cholesterol levels, and high-density lipoprotein (HDL) cholesterol concentrations. Sitting blood pressure was measured  $\approx 30$  to 180 minutes before tonometry. We derived heart rate from a 10-second 12-lead ECG recording.

### CFPWV, CRPWV, and PWV Ratio

Arterial tonometry measures with simultaneous ECG recording were acquired from the radial, femoral, and carotid arteries after  $>5$  minutes of rest in the supine position, as described previously.<sup>17,18</sup> All recordings were performed on the right side of the body. Transit distances were estimated by measuring the body surface distance from the suprasternal notch to each pulse recording site. CFPWV and CRPWV were calculated from tonometry waveforms and body surface measurements, which were adjusted for parallel transmission in the brachiocephalic artery and aortic arch with the use of the suprasternal notch as a fiducial point. We also derived supine mean arterial pressure from integration of the brachial waveform calibrated with oscillometric blood pressure at the time of tonometry. We inverted CFPWV to reduce heteroscedasticity and multiplied by  $-1$  to restore directionality of the association. CRPWV was normally distributed and therefore included in the models without transformation. We defined the aortic–brachial arterial stiffness gradient as a PWV ratio, that is, CRPWV divided by CFPWV. This approach underscores the youthful design of the arterial system, that is, arterial stiffness should normally increase when moving distally in the arterial system. We used the skewed variable as the denominator, which resulted in a normal distribution for PWV ratio.

### Outcomes

The primary outcome was incidence of major CVD disease events, a composite end point of cardiovascular death, fatal or nonfatal myocardial infarction, unstable angina (prolonged ischemic episode with documented reversible ST-segment changes), stroke, and heart failure. Medical records were obtained for all hospitalizations and physician visits related to CVD disease during follow-up and were reviewed by an adjudication panel consisting of 3 investigators. Criteria for these CVD events have been described previously.<sup>19</sup>

### Statistical Methods

We used sex- and 5-year age-specific medians as cutoff points to define high and low PWV. We assessed baseline characteristics in groups cross-classified by high/low CFPWV and CRPWV. We chose this approach to clarify if any potential relation between PWV ratio and CVD outcomes is driven by the numerator (CRPWV) versus the denominator (CFPWV) of the ratio. In addition, we opted to use age- and sex-specific cutoffs instead of a single cutoff because of the strong relationship between age and CFPWV to avoid categorizing individuals in a higher PWV category mainly based on their age. We compared pairwise differences in characteristics between the 4 groups using 2 sample *t* tests and  $\chi^2$  tests. We applied Bonferroni correction on the pairwise comparisons to account for multiple testing. We examined correlates of PWV ratio using Pearson correlation and linear regression. We included age, sex, BMI, diabetes mellitus, smoking, serum total cholesterol, HDL cholesterol, mean arterial pressure (diastolic pressure+ $1/3$ ×pulse pressure), and heart rate as the predictors. Continuous variables were standardized for comparability. We also assessed incidence of CVD events in groups cross-classified by high versus low CFPWV and CRPWV using cumulative incidence plots, log-rank tests, and multivariable-adjusted Cox models, with low CFPWV/high CRPWV as referent. We examined the relation of CFPWV, CRPWV, and PWV ratio as continuous variables with CVD outcomes using multivariable-adjusted Cox regression models. We calculated C statistics for the models to assess model discrimination.<sup>20</sup> We adjusted all multivariable models for age, sex, BMI, diabetes mellitus, smoking, serum total cholesterol, HDL cholesterol, mean arterial pressure, and heart rate. Furthermore, we examined the relations of CFPWV, CRPWV, and PWV ratio with CVD outcomes in subgroups by sex, age, diabetes mellitus, antihypertensive therapy, and CFPWV level. Interactions between the continuous exposure variable and subgroup were tested by entering a product term into the models. A 2-sided value of  $P < 0.05$  was considered statistically significant. All analyses were performed with Stata software version 13.1 (StataCorp, College Station, TX).

### Results

Characteristics for the overall study sample and in subgroups cross-classified by high versus low CFPWV and CRPWV are reported in Table 1. In general, participants with high CFPWV had more adverse CVD risk profiles than those with low CFPWV. In turn, after classification by CFPWV, individuals with high and low CRPWV had relatively similar CVD risk profiles. CFPWV increased, whereas CRPWV remained fairly stable with older age (Figure 1). Consequently, PWV ratio was  $1.36 \pm 0.19$  in participants aged  $<40$  years to  $0.73 \pm 0.21$  in those aged  $\geq 80$  years.

The correlation coefficient between CFPWV and CRPWV was 0.38 ( $P < 0.001$ ). Univariate and multivariable correlates of PWV ratio are reported in Table 2. In univariate analyses, all variables were associated with lower PWV ratio, except sex and serum total cholesterol. In multivariable linear regression with all variables included, older age, male sex, higher BMI, diabetes mellitus, lower HDL cholesterol, mean arterial pressure, and higher heart rate were associated with lower PWV ratio ( $P < 0.001$  for all). These variables explained 52% of variation in PWV ratio.

**Table 1. Baseline Characteristics in Groups Cross-Classified by High vs Low Carotid–Femoral and Carotid–Radial Pulse Wave Velocity**


Characteristic	Overall	Low CFPWW and High CRPWW (1)	Low CFPWW and Low CRPWW (2)	High CFPWW and High CRPWW (3)	High CFPWW and Low CRPWW (4)
n	2114	377	686	706	345
Age, y	60.4±9.5	60.7±9.2	60.4±9.6	60.2±9.7	60.7±9.5
Women, %	56.4	59.4	55.5	55.0	58.0
BMI, kg/m <sup>2</sup>	27.4±4.6	26.2±3.9 <sup>3,4</sup>	26.6±4.2 <sup>3,4</sup>	28.2±4.8 <sup>1,2</sup>	28.4±5.0 <sup>1,2</sup>
Diabetes mellitus, %	8.8	4.5 <sup>3,4</sup>	5.4 <sup>3,4</sup>	12.5 <sup>1,2</sup>	12.5 <sup>1,2</sup>
Current smoker, %	13.5	14.3	13.7	14.3	10.7
Cholesterol, mmol/L	5.2±0.9	5.2±0.9	5.2±0.9 <sup>3</sup>	5.3±1.0 <sup>2,4</sup>	5.2±1.0 <sup>3</sup>
HDL cholesterol, mmol/L	1.4±0.4	1.5±0.5 <sup>3,4</sup>	1.5±0.4 <sup>4</sup>	1.4±0.5 <sup>1</sup>	1.4±0.4 <sup>1,2</sup>
Systolic BP, mm Hg	127±19	122±16 <sup>3,4</sup>	119±16 <sup>3,4</sup>	134±20 <sup>1,2,4</sup>	131±19 <sup>1,2,3</sup>
Diastolic BP, mm Hg	74±10	74±9 <sup>2,3</sup>	70±9 <sup>1,3,4</sup>	79±10 <sup>1,2,4</sup>	74±9 <sup>2,3</sup>
MAP, mm Hg	92±11	90±10 <sup>2,3,4</sup>	87±10 <sup>1,3,4</sup>	97±12 <sup>1,2,4</sup>	93±10 <sup>1,2,3</sup>
Heart rate, bpm	65±11	63±10 <sup>3</sup>	62±10 <sup>3,4</sup>	68±11 <sup>1,2,4</sup>	65±10 <sup>2,3</sup>
BP-lowering therapy, %	30.7	22.3 <sup>3,4</sup>	25.1 <sup>3,4</sup>	36.3 <sup>1,2</sup>	39.4 <sup>1,2</sup>
Diuretics, %	2.8	2.1	1.9	3.8	2.9
β-Blockers, %	13.8	9.8 <sup>4</sup>	14.3	12.7 <sup>4</sup>	19.4 <sup>1,3</sup>
ACE-inhibitors, %	12.7	9.0 <sup>4</sup>	10.6 <sup>4</sup>	14.2	17.7 <sup>1,2</sup>
ARBs, %	2.3	3.5	1.5	2.1	2.9
CCBs, %	8.8	5.3 <sup>4</sup>	7.4 <sup>4</sup>	9.5	13.6 <sup>1,2</sup>
CFPWW, m/s	9.9±3.4	8.5±1.6 <sup>3,4</sup>	8.1±1.6 <sup>3,4</sup>	12.0±4.1 <sup>1,2,4</sup>	11.0±3.1 <sup>1,2,3</sup>
CRPWW, m/s	10.0±1.5	10.8±0.9 <sup>2,3,4</sup>	8.8±0.9 <sup>1,3,4</sup>	11.3±1.1 <sup>1,2,4</sup>	9.1±0.8 <sup>1,2,3</sup>
PWW ratio	1.08±0.3	1.32±0.2 <sup>3,4</sup>	1.13±0.2 <sup>1,3,4</sup>	1.01±0.3 <sup>1,2,4</sup>	0.88±0.2 <sup>1,2,3</sup>

Values are mean±SD for continuous variables or % for categorical variables. Superscript numbers indicate significant difference compared with category 1, 2, 3, or 4 ( $P < 0.05$  with Bonferroni-corrected 2-sample  $t$  test or  $\chi^2$  test). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium-channel blocker; CFPWW, carotid–femoral pulse wave velocity; CRPWW, carotid–radial pulse wave velocity; HDL, high-density lipoprotein; MAP, mean arterial pressure; and PWW, pulse wave velocity.

During follow-up (median, 12.6 years), 248 first CVD events occurred. Figure 2 illustrates the cumulative incidence of CVD events in groups cross-classified by high versus low CFPWW and CRPWW. The CVD incidence rates and both

unadjusted and adjusted hazards ratios increased from low CFPWW to high CFPWW, whereas further cross-classification by CRPWW had only a small effect on the hazard ratios (HRs; Table S1 in the [online-only Data Supplement](#)). Compared with individuals having low CFPWW and high CRPWW, multivariable-adjusted risk of CVD events was not significantly increased in participants having low CFPWW and low CRPWW (HR, 1.19; 95% confidence interval [CI] 0.76–1.87). In turn, participants having high CFPWW and high CRPWW had a similar risk of CVD events (HR, 1.61; 95% CI, 1.04–2.47) compared with those having CFPWW and low CRPWW (HR, 1.61; 95% CI, 1.01–2.57).

When the prognostic significance of CFPWW, CRPWW, and PWW ratio were assessed as continuous variables, only CFPWW (HR, 1.33 per 1-SD increase; 95% CI, 1.10–1.61) and PWW ratio (HR, 1.32 per 1-SD decrease; 95% CI, 1.09–1.59), but not CRPWW (HR, 0.99 per 1-SD increase; 95% CI, 0.86–1.14) reached statistical significance in multivariable-adjusted Cox models (Table 3). C statistics of the models that included CFPWW or PWW ratio were the same ( $C = 0.783$ ). In a sensitivity analysis, we included supine mean arterial pressure derived from integration of the brachial waveform calibrated



**Figure 1.** Mean carotid–femoral pulse wave velocity (cfPWW), carotid–radial pulse wave velocity (crPWW), and pulse wave velocity (PWW) ratio in 10-y age groups. Vertical bars indicate SD.

**Table 2. Univariate and Multivariable Correlates of Lower Pulse Wave Velocity Ratio**

Characteristic	Univariate			Multivariable (Model R <sup>2</sup> =0.52)	
	β±SE	P Value	R <sup>2</sup>	β±SE	P Value
Age, y	0.18±0.004	<0.001	0.44	0.17±0.004	<0.001
Female sex	0.02±0.01	0.052	0.002	0.05±0.01	<0.001
BMI, kg/m <sup>2</sup>	0.05±0.006	<0.001	0.03	0.03±0.005	<0.001
Diabetes mellitus	0.20±0.02	<0.001	0.04	0.08±0.02	<0.001
Current smoking	-0.08±0.02	<0.001	0.01	0.006±0.01	0.61
Total cholesterol, mmol/L	0.002±0.006	0.69	0.0001	-0.003±0.004	0.44
HDL cholesterol, mmol/L	-0.03±0.006	<0.001	0.01	-0.02±0.005	<0.001
MAP, mm Hg	0.07±0.006	<0.001	0.06	0.04±0.004	<0.001
Heart rate, bpm	0.05±0.005	<0.001	0.03	0.03±0.004	<0.001

Coefficients for all continuous variables are reported per 1-SD increase. The variables were included one at a time in the univariate models, whereas all variables were simultaneously included in multivariable model. BMI indicates body mass index; HDL, high-density lipoprotein; and MAP, mean arterial pressure.


with blood pressure at the time of tonometry, instead of sitting auscultatory mean arterial pressure, in the models (Table S2). This did not materially change the results as the multivariable-adjusted HRs for CFPWV, CRPWV, and PWV ratio were 1.23 (95% CI, 1.01–1.51), 0.93 (95% CI, 0.81–1.08), and 1.27 (95% CI, 1.05–1.54), respectively. C statistics for models with CFPWV or PWV ratio were 0.784. We also investigated whether the prognostic significance of CFPWV, CRPWV, and PWV ratio differed between subgroups by sex, age, diabetes mellitus, antihypertensive therapy, and CFPWV level (Table 4). In these analyses, CRPWV was not significantly associated with CVD outcomes in any subgroup. The only significant interaction was observed for CFPWV and age (<70 versus ≥70 years). In the subsample of 427 individuals aged ≥70 years with 109 incident cardiovascular events, the HRs for CVD events per 1-SD increases in CFPWV and CRPWV and per 1-SD decrease in PWV ratio were 1.39 (95%

CI, 1.06–1.82), 0.90 (95% CI, 0.73–1.12), and 1.54 (95% CI, 1.16–2.04), respectively (Table 4).

**Discussion**

In our investigation, we demonstrated that the aortic–brachial arterial stiffness gradient, defined as the ratio between CRPWV and CFPWV, is significantly related to cardiovascular outcomes in the community. However, PWV ratio provides no incremental predictive value for CVD events over common cardiovascular risk factors and CFPWV. In our lower-risk community-dwelling population, we could not replicate the previous findings that underscored the prognostic importance of the PWV ratio in dialysis patients.<sup>14</sup>

The aortic–brachial arterial stiffness gradient is a relatively new concept in arterial research.<sup>21</sup> The stiffness gradient hypothesis is based on previous observations, which have shown that under normal conditions, when aortic stiffness is lower than that of medium-sized muscular conduit arteries,



**Figure 2.** Cumulative incidence of cardiovascular events in groups classified by high vs low carotid–femoral and carotid–radial pulse wave velocity (truncated at 13 y after baseline). CFPWV indicates carotid–femoral pulse wave velocity; and CRPWV, carotid–radial pulse wave velocity.

**Table 3. Risk of Cardiovascular Events Per 1-SD Increase in CFPWV or CRPWV, and Per 1-SD Decrease in PWV Ratio**

Model	CFPWV			CRPWV			PWV Ratio		
	HR (95% CI)	P Value	Model C Statistic	HR (95% CI)	P Value	Model C Statistic	HR (95% CI)	P value	Model C Statistic
Unadjusted	2.27 (2.00–2.59)	<0.001	0.731	1.15 (1.02–1.30)	0.03	0.546	2.22 (1.95–2.54)	<0.001	0.716
Adjusted for MAP	2.31 (2.01–2.65)	<0.001	0.732	1.04 (0.91–1.19)	0.60	0.588	2.17 (1.90–2.49)	<0.001	0.718
Multivariable-adjusted	1.33 (1.10–1.61)	0.004	0.783	0.99 (0.86–1.14)	0.85	0.780	1.32 (1.09–1.59)	0.004	0.783

Multivariable-adjusted model is adjusted for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, total cholesterol, MAP, and high-density lipoprotein cholesterol. CFPWV indicates carotid–femoral pulse wave velocity; CI, confidence interval; CRPWV, carotid–radial pulse wave velocity; HR, hazards ratio; and MAP, mean arterial pressure.

partial pressure wave reflections are generated at the transition of these segments, resulting in attenuated pulse pressure transmission.<sup>17,22–24</sup> However, the aortic–brachial arterial stiffness gradient is reversed with aging in most individuals when aortic stiffness increases considerably while peripheral muscular artery stiffness experiences only minor or nonexistent increases.<sup>1,3–5</sup> This reversal of the stiffness gradient, in turn, has been shown to be associated with less distal reflection and attenuation of the forward pressure wave when it is transmitted to the microcirculation, potentially leading to increased organ damage.<sup>14,21</sup> The transmission of excessive forward pressure may be especially detrimental for high-flow organs such as the brain or the kidney. Indeed, at least 2 studies have shown that increased arterial stiffness by itself is associated

with transmission of increased flow pulsatility into and the brain and kidneys, leading to structural brain damage, microalbuminuria, and kidney injury.<sup>25,26</sup>

Although the stiffness gradient hypothesis is an interesting concept, our findings do not support the notion that measurement of the aortic–brachial arterial stiffness gradient ratio provides additional prognostic value over conventional CFPWV in the community, or in subgroups. Our findings have no direct implications for the validity of the concept, but primarily demonstrate that the loss of stiffness gradient is essentially all attributable to the increase in CFPWV rather than to a decrease in CRPWV. To our knowledge, only 1 published study has previously investigated the prognostic significance of arm/aorta PWV ratio. In this publication,

**Table 4. Risk of Cardiovascular Events Per 1-SD Increase in CFPWV or CRPWV, and Per 1-SD Decrease in PWV Ratio in Subgroups by Age, Sex, and CFPWV Level**

Subgroup	CFPWV		CRPWV		PWV Ratio	
	HR (95% CI)	P for Interaction	HR (95% CI)	P for Interaction	HR (95% CI)	P for Interaction
<b>Sex</b>						
Men (n=921, 130 events)	1.24 (0.95–1.63)	0.63	0.89 (0.73–1.08)	0.24	1.32 (1.02–1.70)	0.83
Women (n=1193, 115 events)	1.46 (1.10–1.93)		1.10 (0.90–1.34)		1.36 (1.02–1.81)	
<b>Age, y</b>						
<60 (n=1053, 56 events)	1.50 (0.98–2.30)	0.88	0.96 (0.71–1.28)	0.24	1.50 (1.02–2.20)	0.37
≥60 (n=1061, 189 events)	1.79 (1.49–2.17)		0.95 (0.80–1.12)		1.82 (1.51–2.18)	
<b>Age, y</b>						
<70 (n=1687, 136 events)	1.95 (1.56–2.44)	0.02	1.07 (0.88–1.29)	0.051	1.77 (1.43–2.19)	0.29
≥70 (n=427, 109 events)	1.39 (1.06–1.82)		0.90 (0.73–1.12)		1.54 (1.16–2.04)	
<b>CFPWV</b>						
Low (n=1063, 91 events)	...	...	0.95 (0.74–1.23)	0.55	...	...
High (n=1051, 154 events)	...		0.91 (0.75–1.09)		...	
<b>Diabetes mellitus</b>						
Yes (n=185, 52 events)	1.22 (0.98–1.52)	0.19	1.01 (0.87–1.18)	0.63	1.19 (0.97–1.47)	0.15
No (n=1929, 193 events)	1.94 (1.23–3.08)		0.91 (0.65–1.27)		2.06 (1.30–3.26)	
<b>BP-lowering therapy</b>						
Yes (n=648, 136 events)	1.26 (0.93–1.69)	0.46	1.05 (0.85–1.30)	0.27	1.19 (0.89–1.57)	0.17
No (n=1466, 109 events)	1.27 (0.99–1.64)		0.99 (0.82–1.21)		1.28 (0.98–1.67)	

Models are adjusted for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, total cholesterol, mean arterial pressure, and high-density lipoprotein cholesterol (age was omitted from the subgroup analyses by age). BP indicates blood pressure; carotid–femoral pulse wave velocity; CRPWV, carotid–radial pulse wave velocity; CI, confidence interval; HR, hazards ratio; and PWV, pulse wave velocity.

Fortier et al<sup>14</sup> assessed the relation of aortic–brachial arterial stiffness gradient and all-cause mortality in 310 adult patients on dialysis. In contrast to our findings, the authors found that the unadjusted HR for all-cause mortality related to 1-SD increase in PWV ratio was 1.43 (95% CI, 1.24–1.64) whereas the HR for a 1-SD increase in CFPWV was 1.29 (95% CI, 1.11–1.50). PWV ratio resulted in a model C statistic of 0.694, whereas the C statistic for a model that included CFPWV was only 0.627. In addition, only PWV ratio, but not CFPWV, CRPWV, or augmentation index (a measure of wave reflection and arterial stiffness), was significantly associated with outcomes after adjustment for other classical cardiovascular risk factors.<sup>14</sup> The discrepancy between our findings and those of Fortier et al on PWV ratio and CVD outcomes may be explained by several factors. First and foremost, our study included a community-based sample whereas the study of Fortier et al included only dialysis patients, a highly selected group of patients with multiple comorbidities, such as hypertension, diabetes mellitus, inflammation, and anemia.<sup>27</sup> In the long term, these patients undergo significant arterial remodeling that is already observed in early-stage chronic kidney disease.<sup>28</sup> And in the short term, both fluid overload and hemodialysis have been shown to have drastic effects on arterial stiffness.<sup>29,30</sup> Another possible cause for the inconsistent results is that the stiffness gradient hypothesis may oversimplify the interaction between the aorta and muscular conduit arteries. The vascular system does not solely consist of 2 tubes attached to each other. Furthermore, previous results have been somewhat mixed even among dialysis patients as in a study by Pannier et al,<sup>2</sup> only aortic stiffness, but not peripheral muscular artery stiffness, predicted cardiovascular mortality. In summary, our observations do not support the use of PWV ratio for CVD risk assessment in the community. We cannot, however, exclude the possibility that PWV ratio might provide incremental predictive value over CFPWV in the elderly. In individuals aged  $\geq 70$  years, the HRs for CVD events per 1-SD increase in CFPWV and per 1-SD decrease in PWV ratio were 1.39 and 1.54, but with widely overlapping CIs. Given these findings, additional larger studies of older individuals are warranted to better assess the predictive value of the PWV ratio in the elderly.

We observed that higher age, male sex, higher BMI, diabetes mellitus, lower HDL cholesterol, higher mean arterial pressure, and higher heart rate were associated with lower PWV ratio. In the study by Fortier et al,<sup>14</sup> only higher age, diabetes mellitus, history of CVD, and lower hemoglobin were related to PWV ratio in a multivariable regression analysis. However, the findings of Fortier et al<sup>14</sup> were limited by their smaller study sample and lack of some relevant clinical variables. However, all of these factors have also been found to be correlates of CFPWV, the apparent main driver of PWV ratio.<sup>17,31</sup> We could not therefore find any correlates that are specific to PWV ratio.

Our study has several strengths that merit comment. For example, our study was performed with a moderately-sized population sample of community-dwelling individuals, which enhanced generalizability and made subgroup analyses feasible. In addition, in contrast to the only previous prognostic study, data were available on CVD outcomes and all relevant

cardiovascular risk factors.<sup>14</sup> Our study also has certain limitations, such as a study sample consisting mainly of middle-aged to older adults of European descent. The extent to which our results are generalizable to other racial or ethnic groups, or to elderly individuals with multiple comorbidities, remains unknown, and warrants further study. In addition, the number of CVD events in some of the groups cross-classified by high/low CFPWV and CRPWV was relatively modest. Nevertheless, the findings from these analyses were consistent with those that modeled PWV ratio as a continuous variable. Furthermore, we cannot exclude residual confounding.

## Perspectives

Our results confirm that CFPWV and PWV ratio are associated with CVD events. Although a recent previous study had reported that PWV ratio might provide incremental predictive value over CFPWV in dialysis patients, we could not validate these findings in a community setting.<sup>14</sup> In fact, nearly all of the prognostic significance of PWV ratio in the general population seems to be driven by CFPWV. Based on our results, CFPWV should remain the criterion standard for assessing vascular stiffness in the community.<sup>32</sup>

## Acknowledgments

We thank the participants of the Framingham Heart Study.

## Sources of Funding

This study was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (National Institutes of Health [NIH] contracts N01-HC-25195 and HHSN268201500001I) and NIH grants HL080124, HL071039, HL077447, HL107385, 1R01HL126136-01A1, 5R01HL107385-04, 1R01HL60040, and 1R01HL70100.

## Disclosures

G.F. Mitchell is owner of Cardiovascular Engineering, Inc., a company that designs and manufactures devices that measure vascular stiffness. The company uses these devices in clinical trials that evaluate the effects of diseases and interventions on vascular stiffness. The remaining authors report no conflicts.

## References

1. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. *Circulation*. 1983;68:50–58.
2. Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. *Hypertension*. 2005;45:592–596. doi: 10.1161/01.HYP.0000159190.71253.c3.
3. Mitchell GF, Vita JA, Larson MG, Parise H, Keyes MJ, Warner E, Vasan RS, Levy D, Benjamin EJ. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. *Circulation*. 2005;112:3722–3728. doi: 10.1161/CIRCULATIONAHA.105.551168.
4. McEnery CM, McDonnell BJ, So A, Aitken S, Bolton CE, Munery M, Hickson SS, Yasmin, Maki-Petaja KM, Cockcroft JR, Dixon AK, Wilkinson IB; Anglo-Cardiff Collaboration Trial Investigators. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. *Hypertension*. 2009;53:524–531. doi: 10.1161/HYPERTENSIONAHA.108.126615.
5. Kimoto E, Shoji T, Shinohara K, Inaba M, Okuno Y, Miki T, Koyama H, Emoto M, Nishizawa Y. Preferential stiffening of central over peripheral arteries in type 2 diabetes. *Diabetes*. 2003;52:448–452.
6. van der Heijden-Spek JJ, Staessen JA, Fagard RH, Hoeks AP, Boudier HA, van Bortel LM. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. *Hypertension*. 2000;35:637–642.

7. Cameron JD, Bulpitt CJ, Pinto ES, Rajkumar C. The aging of elastic and muscular arteries: a comparison of diabetic and nondiabetic subjects. *Diabetes Care*. 2003;26:2133–2138.
8. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*. 2014;63:636–646. doi: 10.1016/j.jacc.2013.09.063.
9. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation*. 2006;113:664–670. doi: 10.1161/CIRCULATIONAHA.105.579342.
10. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. *Hypertension*. 1999;33:1111–1117.
11. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. *Circulation*. 1999;99:2434–2439.
12. Mitchell GF, Hwang SJ, Vasani RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation*. 2010;121:505–511. doi: 10.1161/CIRCULATIONAHA.109.886655.
13. Tillin T, Chambers J, Malik I, Coady E, Byrd S, Mayet J, Wright AR, Kooner J, Shore A, Thom S, Chaturvedi N, Hughes A. Measurement of pulse wave velocity: site matters. *J Hypertens*. 2007;25:383–389. doi: 10.1097/HJH.0b013e3280115bea.
14. Fortier C, Mac-Way F, Desmeules S, Marquis K, De Serres SA, Lebel M, Boutouyrie P, Agharazii M. Aortic-brachial stiffness mismatch and mortality in dialysis population. *Hypertension*. 2015;65:378–384. doi: 10.1161/HYPERTENSIONAHA.114.04587.
15. Covic A, Siritopol D. Pulse wave velocity ratio: the new “gold standard” for measuring arterial stiffness. *Hypertension*. 2015;65:289–290. doi: 10.1161/HYPERTENSIONAHA.114.04678.
16. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol*. 1979;110:281–290.
17. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasani RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. *Hypertension*. 2004;43:1239–1245. doi: 10.1161/01.HYP.0000128420.01881.aa.
18. Mitchell GF, Guo CY, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasani RS, Levy D. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. *Circulation*. 2007;115:2628–2636. doi: 10.1161/CIRCULATIONAHA.106.667733.
19. Kannel WB, Wolf PA, Garrison RJ, editor. *Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements. Framingham Heart Study, 30 Year Follow-Up*. Bethesda, MD: US Department of Health and Human Services; 1987.
20. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasani RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008;27:157–172; discussion 207. doi: 10.1002/sim.2929.
21. Fortier C, Agharazii M. Arterial Stiffness Gradient. *Pulse (Basel)*. 2016;3:159–166. doi: 10.1159/000438852.
22. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. *Kidney Int*. 2012;82:388–400. doi: 10.1038/ki.2012.131.
23. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol (1985)*. 2008;105:1652–1660. doi: 10.1152/jappphysiol.90549.2008.
24. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. *Hypertension*. 2005;46:200–204. doi: 10.1161/01.HYP.0000168052.00426.65.
25. Mitchell GF, van Buchem MA, Sigurdsson S, Gotal JD, Jonsdottir MK, Kjartansson Ó, Garcia M, Aspelund T, Harris TB, Gudnason V, Launer LJ. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility–Reykjavik study. *Brain*. 2011;134(pt 11):3398–3407. doi: 10.1093/brain/awr253.
26. Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. *Hypertension*. 2011;58:839–846. doi: 10.1161/HYPERTENSIONAHA.111.177469.
27. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. *Circulation*. 2007;116:85–97. doi: 10.1161/CIRCULATIONAHA.106.678342.
28. Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houillier P, Boutouyrie P. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. *Kidney Int*. 2006;69:350–357. doi: 10.1038/sj.ki.5000047.
29. Ögünç H, Akdam H, Alp A, Gencer F, Akar H, Yeniçerioglu Y. The effects of single hemodialysis session on arterial stiffness in hemodialysis patients. *Hemodial Int*. 2015;19:463–471. doi: 10.1111/hdi.12277.
30. Kocyigit I, Sipahioglu MH, Orselik O, Unal A, Celik A, Abbas SR, Zhu F, Tokgoz B, Dogan A, Oymak O, Kotanko P, Levin NW. The association between arterial stiffness and fluid status in peritoneal dialysis patients. *Perit Dial Int*. 2014;34:781–790. doi: 10.3747/pdi.2013.00057.
31. Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. *Eur Heart J*. 2010;31:2338–2350.
32. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006;27:2588–2605. doi: 10.1093/eurheartj/ehl254.

## Novelty and Significance

### What Is New?

- A recent study reported that the aortic-brachial arterial stiffness gradient, defined as the ratio of carotid–radial and carotid–femoral pulse wave velocity, is a better predictor of all-cause mortality than carotid–femoral pulse wave velocity in dialysis patients.
- The role of the arterial stiffness gradient as a cardiovascular risk factor has not been validated in the community.

### What Is Relevant?

- The arterial stiffness gradient provided no incremental predictive value for cardiovascular events over common cardiovascular risk factors and

carotid–femoral pulse wave velocity in a lower-risk community-dwelling population.

### Summary

Carotid–femoral pulse wave velocity should remain the criterion standard for assessing vascular stiffness in the community.

## Aortic–Brachial Arterial Stiffness Gradient and Cardiovascular Risk in the Community: The Framingham Heart Study

Teemu J. Niiranen, Bindu Kalesan, Martin G. Larson, Naomi M. Hamburg, Emelia J. Benjamin,  
Gary F. Mitchell and Ramachandran S. Vasani

*Hypertension*. 2017;69:1022-1028; originally published online April 10, 2017;  
doi: 10.1161/HYPERTENSIONAHA.116.08917

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231  
Copyright © 2017 American Heart Association, Inc. All rights reserved.  
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the  
World Wide Web at:

<http://hyper.ahajournals.org/content/69/6/1022>

Data Supplement (unedited) at:

<http://hyper.ahajournals.org/content/suppl/2017/04/11/HYPERTENSIONAHA.116.08917.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Hypertension* is online at:  
<http://hyper.ahajournals.org/subscriptions/>



**ONLINE SUPPLEMENT**

**AORTIC-BRACHIAL ARTERIAL STIFFNESS GRADIENT AND CARDIOVASCULAR RISK IN  
THE COMMUNITY: THE FRAMINGHAM HEART STUDY**

Teemu J. Niiranen, MD, Bindu Kalesan, PhD, Martin G. Larson, SD,  
Naomi M. Hamburg, MD, MS, Emelia J. Benjamin MD, ScM,  
Gary F. Mitchell, MD, Ramachandran S. Vasani, MD

Corresponding Author:

Teemu J. Niiranen, Framingham Heart Study, 73 Mt. Wayte Avenue, Suite 2, Framingham, MA  
01702. e-mail: [teemu.niiranen@thl.fi](mailto:teemu.niiranen@thl.fi); tel: +1-508-872-6562; fax: +1- 508-626-1262

*Table S1.* Incidence and risk of cardiovascular events in groups cross-classified by high versus low carotid-femoral and carotid-radial pulse wave velocity.

Incidence / Risk Estimate	Low CFPWV and High CRPWV	Low CFPWV and Low CRPWV	High CFPWV and High CRPWV	High CFPWV and Low CRPWV
Number of CVD events (%)	28 (7.4%)	63 (9.2%)	104 (14.7%)	50 (14.5%)
Events per 1000 person-yrs	0.55 (0.38-0.80)	0.66 (0.52-0.85)	1.13 (0.93-1.37)	1.12 (0.85-1.48)
Hazard ratio (95% CI) for CVD events				
Adjusted for age and sex	1.00 (reference)	1.14 (0.73-1.78)	2.04 (1.34-3.09)†	1.97 (1.24-3.13)†
Multivariable-adjusted model	1.00 (reference)	1.19 (0.76-1.87)	1.61 (1.04-2.47)*	1.61 (1.01-2.57)*

CFPWV, carotid-femoral pulse wave velocity; CRPWV, carotid-radial pulse wave velocity; CI, confidence interval; CVD, cardiovascular disease. Multivariable model adjusted for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, total cholesterol, mean arterial pressure, and HDL cholesterol. \* $P < 0.05$ ; † $P < 0.01$ .

*Table S2.* Risk of cardiovascular events per 1-SD increase in carotid-femoral or carotid-radial pulse wave velocity, and per 1-SD decrease in pulse wave velocity ratio. Mean arterial pressure derived from the brachial waveform was used in the analyses.

Model	CFPWV			CRPWV			PWV ratio		
	HR (95% CI)	<i>P</i> value	Model c-statistic	HR (95% CI)	<i>P</i> value	Model c-statistic	HR (95% CI)	<i>P</i> value	Model c-statistic
Unadjusted	2.27 (2.00-2.59)	<0.001	0.731	1.15 (1.02-1.30)	0.03	0.546	2.22 (1.95-2.54)	<0.001	0.716
Adjusted for MAP	2.18 (1.88-2.51)	<0.001	0.732	0.93 (0.81-1.07)	0.29	0.631	2.08 (1.81-2.38)	<0.001	0.728
Multivariable-adjusted	1.23 (1.01-1.51)	0.04	0.784	0.93 (0.81-1.08)	0.35	0.782	1.27 (1.05-1.54)	0.01	0.784

CFPWV, carotid-femoral pulse wave velocity; CRPWV, carotid-radial pulse wave velocity; HR, hazard ratio; CI, confidence interval; MAP, mean arterial pressure derived from the brachial waveform. Multivariable-adjusted model is adjusted for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, total cholesterol, mean arterial pressure and HDL cholesterol.